Aprea Therapeutics
Doylestown, Pennsylvania, United States · Biotechnology, Health Care, Science And Engineering · 9 employees
Aprea Therapeutics (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. We exist to ensure that cancer doesn't interrupt life's possibilities and dreams. We do this through our unique approach to synthetic lethality that is revolutionizing the future of cancer treatment.
Funding history
- Funding Round — $3.1M — Dec 2025
- Funding Round — $34.0M — Mar 2024
- Funding Round — $34.0M — Mar 2024
Recent signals
- Jan 09, 2026: SEC 8-K (8.01): On January 9, 2026, Aprea Therapeutics, Inc. updated its corporate presentation slide deck, indicating a strategic communication to its stakeholders regarding its business outlook or operational updates. This update may involve new insights or developments that are important for investors and may reflect the latest strategic initiatives. The corporate presentation slide deck is filed as Exhibit 99.1, which includes detailed information pertinent to the company's ongoing activities or projections, crucial for shareholders and other interested parties.
- Dec 29, 2025: Raised $3.1M
- Mar 11, 2025: Aprea Therapeutics Announces Material Transfer Agreement with MD Anderson Cancer Center for APR-1051
- May 02, 2024: Aprea Therapeutics Appoints Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer
- Mar 18, 2024: Raised $34.0M
- Mar 12, 2024: Raised $34.0M
- Feb 28, 2023: Raised funding
- May 16, 2022: Acquired Aprea Therapeutics Announces Acquisition Of Atrin Pharmaceuticals Inc. And Reports First Quarter 2022 Financial Results
See plans & pricing → Track Aprea Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.